Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | CARTITUDE-1 final results: cilta-cel in heavily pretreated patients with R/R myeloma

Yi Lin • 4 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1 CARTITUDE-4

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the final results of the CARTITUDE-1 trial (NCT03548207), which is evaluating ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma. Dr Lin summarizes the median progression-free survival (PFS) observed in patients, and further shares her excitement for the Phase III CARTITUDE-4 trial (NCT04181827). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals